Lilly Buys Psychedelics Maker Atai Beckley for $2.8B
Eli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
Explore withdrawal approaches for portfolios with SP 500 and Total Stock Market funds to sustain income and minimize risk.
28,406 articlesEli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
NVIDIA CEO Jensen Huang positioned the latest AI stock pullback as a buying opportunity, a stance that reminds invest...
SpaceX’s impending IPO is driving the launch of leveraged ETFs designed to amplify bets on the rocket company, offeri...
Take a pause this weekend to dive into long-form investing stories. From the science behind durable moats to how ever...
Understanding James River (JRVR) earnings means decoding insurance results, investment income, and risk management. T...
Two North American midstream giants posted earnings that point to divergent paths for dividend investors in 2026. ENB...
Machi Big Brother’s high-stakes run appears to be nearing an end as his Hyperliquid balance drops below $1 million. T...
A new wave of on-chain data shows the majority of XRP in circulation remains underwater, signaling potential selling ...
Could XRP slip below $1 in a year? This in-depth guide weighs the prediction: (ripple) will worth against regulatory,...
Prediction markets tied to the World Cup final surge to record volumes, with Spain favored over Argentina as betting ...
Looking for a simple, durable path to cash flow and growth? This article breaks down three reliable dividend stocks h...
Fintech investing has moved fast. This article compares PayPal and SoFi, explains whether PayPal is truly yesterday's...